In NIH trial, selumetinib shrinks tumors, provides clinical benefit for children with NF1

Having trouble viewing this email? View it as a Web page.

Bookmark and Share

You are receiving this message because you are subscribed to News Releases for National Institutes of Health (NIH).

 

03/18/2020 05:00 PM EDT

Children experienced reduced pain, improved function, and better overall quality of life.

This email was sent to ymilov@gmail.com using GovDelivery Communications Cloud on behalf of: National Institutes of Health (NIH) · 9000 Rockville Pike · Bethesda MD 20892 · 301-496-4000 / TTY 301-402-9612 GovDelivery logo